This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Sirtuin 1 (SIRT1)	<p>An SAR study identified a series of acetylated lysine analogs as SIRT1 inhibitors that could help treat cancer. <i>In vitro</i>, the most potent inhibitor had high selectivity for SIRT1 over that for SIRT2 and SIRT3. In human colon cancer cells, the compound caused a dose-dependent increase in the level of acetylated p53, indicating effective SIRT1 inhibition in the cells. Next steps include increasing the potency and selectivity of the SIRT1 inhibitors as well as examining their <i>in vivo</i> activity.</p> <p>Elixir Pharmaceuticals Inc. has a SIRT1 inhibitor in preclinical development to treat Huntington's disease (HD) and certain cancers.</p> <p>SciBX 2(19); doi:10.1038/scibx.2009.783 Published online May 14, 2009</p>	Unpatented; unlicensed	<p>Asaba, T. <i>et al. J. Am. Chem. Soc.</i>; published online May 4, 2009; doi:10.1021/ja807083y</p> <p>Contact: Naoki Miyata, Nagoya City University, Nagoya, Aichi, Japan e-mail: miyata-n@phar.nagoya-cu.ac.jp</p> <p>Contact: Takayoshi Suzuki, same affiliation as above e-mail: suzuki@phar.nagoya-cu.ac.jp</p>